Unlearn®, a San Francisco, California-based developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, announced that it closed a $50 million Series B funding.

The round was led by New York-based global venture capital and private equity firm Insight Partners with participation from new investor Radical Ventures, as well as all of the company’s existing investors including 8VC, DCVC, DCVC Bio, and Mubadala Capital Ventures. 

Through its investment, Dylan Morris, Managing Director, Insight Partners, has joined the Unlearn Board of Directors.

Company: Unlearn.AI Inc.

Raised: $50.0M

Round: Series B

Funding Month: April 2022

Lead Investors: Insight Partners

Additional Investors: 8VC, DCVC, DCVC Bio, and Mubadala Capital Ventures

Company Website: https://www.unlearn.ai/

Software Category: Clinical Trials

About the Company: Unlearn.AI is the only company creating TwinRCTs™, which combines AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials. Unlearn’s technology has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. Unlearn is partnering with the world’s leading pharma companies, including Merck KGaA, Darmstadt, Germany, and continues to have discussions with regulators. The European Medicines Agency (EMA) published a draft qualification opinion for PROCOVA™ — a patent-pending method developed by Unlearn for leveraging historical data and machine learning to reduce sample sizes or increase power in Phase 2 or 3 clinical trials.

Source: https://www.businesswire.com/news/home/20220419005354/en/Unlearn-Closes-50-Million-Series-B-Funding-to-Advance-the-Use-of-Its-Machine-Learning-Powered-TwinRCTs%E2%84%A2-in-Clinical-Trials